SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is experiencing a significant surge in momentum as the community anticipates groundbreaking clinical data for pancreatic and brain cancer treatments scheduled for presentation at major medical conferences. Investors are actively discussing the stock's transition into a catalyst-heavy phase, with enthusiasm fueled by favorable interim study results and recent analyst price target upgrades.

Inter & Co., Inc. Is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Banking, Securities, Insurance Brokerage, Marketplace, Asset Management, Service, and Other. The Banking segment offers checking accounts cards, deposits, loans and advances, and other services through mobile application. The Securities segment is involved in the acquisition, sale and custody of securities, the structuring and distribution of securities in the capital market, and the provision of administration services to investment funds. The Insurance Brokerage segment includes insurance products underwritten by insurance companies, such as warranties, life, property and automobile insurance, and pension products, as well as consortium products provided by a third party. The Marketplace segment operates a digital platform, which offers goods and services to its customers. The Asset Management segment is composed of the operations related to the management of fund portfolios and other assets. The Service segment consists of collection and management of personal information, development and licensing of customized computer programs, development and licensing of non-customized computer programs and technical support, maintenance, and other information technology services. The company was founded on January 26, 2021 and is headquartered in Belo Horizonte, Brazil.

Inter & Co Inc - Ordinary Shares - Class A

INTER  CO INC

Inter & Co is capturing investor attention as it expands its AI-powered super app strategy and targets record growth, leading many in the community to view the stock as undervalued despite recent price volatility. While some participants are wary of macroeconomic headwinds, bulls are actively discussing the company's strong client acquisition and long-term potential, with many advocating for buying into current support levels.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased trading activity as market participants digest a significant portfolio shake-up involving Berkshire Hathaway's full exit from the stock, which many community members view as a misplaced move following the company's recent strong performance and solid fundamentals. Traders are actively debating the stock's future trajectory, with many dismissing the recent price dip as an overreaction and identifying it as a buying opportunity in a defensive leader poised for continued growth.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is attracting attention as it secures a significant purchase order for its SiCore silicon-anode batteries to power electric two and three-wheelers in the Chinese market. The community is actively debating the company's long-term growth potential and manufacturing strategy, with many monitoring whether warrant exchange activities and short interest levels will act as catalysts for future price movement.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently facing significant selling pressure as Treasury yields climb toward 5%, driven by intensifying inflation fears tied to the ongoing conflict in the Middle East and rising energy costs. Market participants are actively discussing the possibility of a debt-driven volatility spike, with many investors hedging against further downside through heavy put option activity while debating whether this represents a long-term bottom or the start of a deeper bond market rout.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as investors weigh strong demand for its AI-focused high-speed networking gear against concerns over potential margin pressures from industry-wide supply chain constraints. The community is actively debating the stock's long-term potential as a critical AI infrastructure provider, often comparing its recent volatility to other sector leaders like Cisco while highlighting institutional analyst upgrades.

Alpha Pro Tech Ltd. engages in the business of protecting people, products and environment. It develops, manufactures and markets disposable and limited use protective apparel products for the industries, clean room, medical and dental markets. The company operates through the Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment includes many different styles of disposable products, such as shoe covers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products. The Building Supply segment consists of a line of construction supply weatherization products, namely house wrap and synthetic roof underlayment. The company was founded in 1983 and is headquartered in Aurora, Canada.

Alpha Pro Tech Ltd.

Alpha Pro Tech is seeing renewed market interest driven by recent news headlines regarding respiratory viruses, causing traders to revisit the stock as a potential protective equipment play. The community is actively debating the stock's valuation relative to its tangible book value, with some seeing a bargain while others express skepticism over the lack of sustained growth catalysts outside of pandemic-related spikes.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the announcement of an exclusive supply agreement for the Tokyo-172 strain of BCG, a development investors hope will resolve long-standing U.S. supply shortages and bolster the commercial rollout of Anktiva. Community sentiment remains focused on the companys ongoing participation in the American Urological Association annual meeting, with many long-term shareholders anticipating that resolving supply bottlenecks and recent leadership changes at the FDA will accelerate clinical progress and alleviate short-selling pressure.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense volatility as investors weigh a major institutional funding round at a premium against ongoing concerns over valuation and short-selling campaigns. The community remains sharply divided, with bulls pointing to the company's new AI networking partnerships as validation, while bears continue to scrutinize the company's operational transparency and recent share issuance.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as the community closely monitors the impending 80th clinical trial event for its lead asset, GPS, while institutional buying momentum intensifies following recent 13F filings. Investors are actively discussing the potential for a transformative breakthrough in AML therapies, with many highlighting the stock's significant long-term potential as it nears critical data readouts and institutional ownership increases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Do Options Traders Know Something About Adherex Technologies Stock We Don't?

Investors need to pay close attention to FENC stock based on the movements in the options market lately. 

Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates

Adherex Technologies (FENC) delivered earnings and revenue surprises of +157.14% and +8.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of +57.90% and +31.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies (FENC) Expected to Announce Quarterly Earnings on Tuesday

Adherex Technologies (NASDAQ:FENC) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-fennec-pharmaceuticals-inc-stock...

Insider Selling: Adherex Technologies (NASDAQ:FENC) Director Sells 10,781 Shares of Stock

Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,781 shares of the business's stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $6.47, for a total value of $69,753.07. Following the sale, the director owned...

Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock...

Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving Average - Here's What Happened

Fennec Pharmaceuticals (TSE:FRX) Stock Passes Below Fifty Day Moving Average - What's Next...

Adherex Technologies (NASDAQ:FENC) Given "Outperform" Rating at Wedbush

Wedbush reiterated an "outperform" rating and issued a $13.00 target price on shares of Adherex Technologies in a research note on Thursday...

Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving Average   - What's Next?

Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving Average - Here's What Happened...

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Current Price	$9.75
Prev Close	$9.24
Open	$9.29
Dividend Yield	N/A
50-Day Moving Average	$6.90
Beta	1.03
Avg. Volume	147,677.51
PE Ratio	-32.92

52-Week High	$10.17
52-Week Low	$5.65
Market Capitalization	$338.69M
EPS (Annual)	-$0.3409
Price to Book	8.94
Revenue Per Employee	$1.28M

FENC
Fennec Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FENC News

FENCFennec Pharmaceuticals Inc